Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-313 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-313.
Tmax of ABBV-313.
Beta of ABBV-313.
t1/2 of ABBV-313.
AUCt of ABBV-313.
| Arm | Type | Description |
|---|---|---|
| Part 1, Group 1: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 2: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 3: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 4: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 5: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 1, Group 6: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive a single dose of ABBV-313 or Placebo |
| Part 2, Group 7: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive multiple doses of ABBV-313 or Placebo |
| Part 2, Group 8: ABBV-313 or Placebo | EXPERIMENTAL | Participants will receive multiple doses of ABBV-313 or Placebo |
| Name | Type | Description |
|---|---|---|
| ABBV-313 | DRUG | Injection |
| Placebo | DRUG | Injection |
Inclusion Criteria: * BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, v...
ABBV-313 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to assess its safety, tolerability, and how single and multiple injections or infusions affect the body of adult participants. It is not approved for any medical condition.
ABBV-313 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and tolerability in healthy adult volunteers.
ABBV-313 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 study is recruiting participants to evaluate the safety, tolerability, and effects of single and multiple doses of the drug.
ABBV-313 is being studied in one active Phase 1 clinical trial with the identifier NCT07673120. This randomized, double-blind, controlled study is recruiting 64 healthy adult participants in the United States to assess the safety, tolerability, and effects of single and multiple injections or infusions of the drug.
Yes, ABBV-313 is a small molecule drug. It is being developed as an injectable or infusion formulation for administration to adult participants in a Phase 1 clinical trial. The study is designed to evaluate how the drug affects the body when given as single or multiple doses.